Literature DB >> 21520173

Constitutional telomerase mutations are genetic risk factors for cirrhosis.

Rodrigo T Calado1, Jennifer Brudno, Paulomi Mehta, Joseph J Kovacs, Colin Wu, Marco A Zago, Stephen J Chanock, Thomas D Boyer, Neal S Young.   

Abstract

UNLABELLED: Some patients with liver disease progress to cirrhosis, but the risk factors for cirrhosis development are unknown. Dyskeratosis congenita, an inherited bone marrow failure syndrome associated with mucocutaneous anomalies, pulmonary fibrosis, and cirrhosis, is caused by germline mutations of genes in the telomerase complex. We examined whether telomerase mutations also occurred in sporadic cirrhosis. In all, 134 patients with cirrhosis of common etiologies treated at the Liver Research Institute, University of Arizona, between May 2008 and July 2009, and 528 healthy subjects were screened for variation in the TERT and TERC genes by direct sequencing; an additional 1,472 controls were examined for the most common genetic variation observed in patients. Telomere length of leukocytes was measured by quantitative polymerase chain reaction. Functional effects of genetic changes were assessed by transfection of mutation-containing vectors into telomerase-deficient cell lines, and telomerase activity was measured in cell lysates. Nine of the 134 patients with cirrhosis (7%) carried a missense variant in TERT, resulting in a cumulative carrier frequency significantly higher than in controls (P = 0.0009). One patient was homozygous and eight were heterozygous. The allele frequency for the most common missense TERT variant was significantly higher in patients with cirrhosis (2.6%) than in 2,000 controls (0.7%; P = 0.0011). One additional patient carried a TERC mutation. The mean telomere length of leukocytes in patients with cirrhosis, including six mutant cases, was shorter than in age-matched controls (P = 0.0004).
CONCLUSION: Most TERT gene variants reduced telomerase enzymatic activity in vitro. Loss-of-function telomerase gene variants associated with short telomeres are risk factors for sporadic cirrhosis.
Copyright © 2011 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21520173      PMCID: PMC3082730          DOI: 10.1002/hep.24173

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  50 in total

1.  Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery.

Authors:  K L Rudolph; S Chang; M Millard; N Schreiber-Agus; R A DePinho
Journal:  Science       Date:  2000-02-18       Impact factor: 47.728

Review 2.  Dyskeratosis congenita in all its forms.

Authors:  I Dokal
Journal:  Br J Haematol       Date:  2000-09       Impact factor: 6.998

3.  A functional polymorphism of the stromelysin gene (MMP-3) influences susceptibility to primary sclerosing cholangitis.

Authors:  J Satsangi; R W Chapman; N Haldar; P Donaldson; S Mitchell; J Simmons; S Norris; S E Marshall; J I Bell; D P Jewell; K I Welsh
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

Review 4.  Switching and signaling at the telomere.

Authors:  E H Blackburn
Journal:  Cell       Date:  2001-09-21       Impact factor: 41.582

5.  Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c.

Authors:  T Poynard; V Ratziu; F Charlotte; Z Goodman; J McHutchison; J Albrecht
Journal:  J Hepatol       Date:  2001-05       Impact factor: 25.083

6.  Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy.

Authors:  Y Shiratori; F Imazeki; M Moriyama; M Yano; Y Arakawa; O Yokosuka; T Kuroki; S Nishiguchi; M Sata; G Yamada; S Fujiyama; H Yoshida; M Omata
Journal:  Ann Intern Med       Date:  2000-04-04       Impact factor: 25.391

7.  Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C.

Authors:  T Poynard; J McHutchison; G L Davis; R Esteban-Mur; Z Goodman; P Bedossa; J Albrecht
Journal:  Hepatology       Date:  2000-11       Impact factor: 17.425

8.  The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita.

Authors:  T Vulliamy; A Marrone; F Goldman; A Dearlove; M Bessler; P J Mason; I Dokal
Journal:  Nature       Date:  2001-09-27       Impact factor: 49.962

9.  Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct.

Authors:  P Hammel; A Couvelard; D O'Toole; A Ratouis; A Sauvanet; J F Fléjou; C Degott; J Belghiti; P Bernades; D Valla; P Ruszniewski; P Lévy
Journal:  N Engl J Med       Date:  2001-02-08       Impact factor: 91.245

Review 10.  Telomere diseases.

Authors:  Rodrigo T Calado; Neal S Young
Journal:  N Engl J Med       Date:  2009-12-10       Impact factor: 91.245

View more
  64 in total

Review 1.  Telomeres and immune competency.

Authors:  Nan-ping Weng
Journal:  Curr Opin Immunol       Date:  2012-05-22       Impact factor: 7.486

2.  Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS.

Authors:  Xin Zhao; Xin Tian; Sachiko Kajigaya; Caroline R Cantilena; Stephen Strickland; Bipin N Savani; Sanjay Mohan; Xingmin Feng; Keyvan Keyvanfar; Neil Dunavin; Danielle M Townsley; Bogdan Dumitriu; Minoo Battiwalla; Katayoun Rezvani; Neal S Young; A John Barrett; Sawa Ito
Journal:  Br J Haematol       Date:  2016-07-19       Impact factor: 6.998

Review 3.  Understanding telomere diseases through analysis of patient-derived iPS cells.

Authors:  Luis F Z Batista; Steven E Artandi
Journal:  Curr Opin Genet Dev       Date:  2013-08-28       Impact factor: 5.578

4.  Short telomeres result in chromosomal instability in hematopoietic cells and precede malignant evolution in human aplastic anemia.

Authors:  R T Calado; J N Cooper; H M Padilla-Nash; E M Sloand; C O Wu; P Scheinberg; T Ried; N S Young
Journal:  Leukemia       Date:  2011-10-18       Impact factor: 11.528

Review 5.  The genetics of dyskeratosis congenita.

Authors:  Philip J Mason; Monica Bessler
Journal:  Cancer Genet       Date:  2011-12

Review 6.  Telomere dynamics in mice and humans.

Authors:  Rodrigo T Calado; Bogdan Dumitriu
Journal:  Semin Hematol       Date:  2013-04       Impact factor: 3.851

Review 7.  Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy.

Authors:  Renumathy Dhanasekaran; Jean-Charles Nault; Lewis R Roberts; Jessica Zucman-Rossi
Journal:  Gastroenterology       Date:  2018-11-04       Impact factor: 22.682

Review 8.  From cirrhosis to hepatocellular carcinoma: new molecular insights on inflammation and cellular senescence.

Authors:  Gayatri Ramakrishna; Archana Rastogi; Nirupama Trehanpati; Bijoya Sen; Ritu Khosla; Shiv K Sarin
Journal:  Liver Cancer       Date:  2013-08       Impact factor: 11.740

9.  Defective telomere elongation and hematopoiesis from telomerase-mutant aplastic anemia iPSCs.

Authors:  Thomas Winkler; So Gun Hong; Jake E Decker; Mary J Morgan; Chuanfeng Wu; William M Hughes; Yanqin Yang; Danny Wangsa; Hesed M Padilla-Nash; Thomas Ried; Neal S Young; Cynthia E Dunbar; Rodrigo T Calado
Journal:  J Clin Invest       Date:  2013-04-15       Impact factor: 14.808

10.  Telomere length and telomerase complex mutations in pediatric acute myeloid leukemia.

Authors:  A M Aalbers; R T Calado; N S Young; C M Zwaan; C Wu; S Kajigaya; E A Coenen; A Baruchel; K Geleijns; V de Haas; G J L Kaspers; T W Kuijpers; D Reinhardt; J Trka; M Zimmermann; R Pieters; V H J van der Velden; M M van den Heuvel-Eibrink
Journal:  Leukemia       Date:  2013-02-21       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.